Title: Advances in antiarrhythmic treatment
- Krzysztof J. Filipiak, Dariusz A. Kosior
- Review articles
- Polish Journal of Cardiology
- Start page:
- Final page:
- antiarrhythmic treatment, pure class III agents, implantable cardioverter-defibrillator
Emerging interest in III class antiarrhythmic agents according to Vaughan-Williams classification has been recently observed despite the unquestionable progress in non-pharmacological methods of arrhythmia management. Although the indications for antiarrhythmic agents has been minimised, the new drugs of this kind are entering the pharmaceutical markets. Ibutilide – the first agent more selective for atrial flutter than for atrial fibrillation is now available for clinical practice, and another agent of this group – dofetilide – has been just registered in USA for oral treatment of new-onset atrial fibrillation. Ambasilide and azimilide are the next ones to come. Much attention is given for studying amiodarone derivatives which are deprived of its adverse effects. Dronedarone is one of the most promising amiodarone-like drugs. The clinical pharmacology of ibutilide is discussed in this paper and new findings about amiodarone and its effectiveness in out-hospital cardiac arrest are presented. Recently revised Canadian standards for the arrhythmia management are described, in which implantable cardioverter-defibrillators are considered to be the first-line treatment in some specified cases.